Concise Prescribing Info
Listed for Dosage.
Dosage/Direction for Use
Adult : SC Growth hormone deficiency Initial: 6 mcg/kg/day. May increase dose gradually. Max: 12.5 mcg/kg/day. HIV-associated wasting or cachexia 0.1 mg/kg/day at bedtime. May take on alternate days for patients at increased risk of adverse effects. Max: 6 mg/day. Short bowel syndrome100 mcg/kg/day for 4 wk. Max: 8 mg/day.
Dosage Details
Children with short stature homeobox-containing (SHOX) deficiency
Child: 50 mcg/kg/day may be used.

Growth retardation due to chronic renal insufficiency, Turner's syndrome
Child: 45-50 mcg/kg or 1.4 mg/m2 daily.

Growth retardation in children who were born small for gestational age, Prader-Will syndrome
Child: 35 mcg/kg or 1 mg/m2 daily. Max: 2.7 mg daily.

Growth hormone deficiency
Adult: Initially, 6 mcg/kg daily. May increase gradually according to patient response. Max: 12.5 mcg/kg/day. Reassess 9 mth after starting treatment.
Child: 25-35 mcg/kg daily. Reassess 9 mth after starting treatment.
Elderly: Lower doses may be required.

Short bowel syndrome
Adult: 100 mcg/kg/day for 4 wk. Max: 8 mg/day.

HIV-associated wasting or cachexia
Adult: 0.1 mg/kg daily at bedtime. May be taken on alternate days for patients at increased risk of adverse effects. Max: 6 mg/day.
Acute critical illness due to heart or abdominal surgery, multiple accidental trauma or respiratory failure; active neoplasms, proliferative or preproliferative diabetic retinopathy; lactation; patients with closed epiphyses. Intracranial lesions. Patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment.
Special Precautions
Monitor thyroid function; benign intracranial hypertension. DM; may require dose reduction in insulin. Pregnancy. Discontinue treatment if there is evidence of tumour growth. Monitoring in patients with scoliosis is recommended due to risk of progression of scoliosis.
Adverse Reactions
Hypothyroidism, peripheral oedema; headache; muscle and joint pain; benign intracranial hypertension. Loss of glycaemic control in diabetics.
Parenteral/SC: C
Drug Interactions
High doses of corticosteroid may inhibit growth-promoting effects of somatropin.
Description: Somatropin is a synthetic human growth hormone of recombinant DNA origin. It stimulates skeletal and soft tissue growth by promoting cell division, amino acid uptake and protein synthesis. It also possesses both insulin-like and diabetogenic effects.
Absorption: Well absorbed (SC/IM). Bioavailability ranges from 60-80%.
Metabolism: Renal and hepatic.
Excretion: Via bile. Elimination half-life: 20-30 min (IV), 3-5 hr (SC/IM).
Store at 2-8°C.
Disclaimer: This information is independently developed by MIMS based on Somatropin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by
  • Norditropin Nordilet
  • Norditropin SimpleXx
  • Saizen
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in